Share this video  

EHA 2022 | Updates on tafasitamab for the treatment of DLBCL

In this video, Wojciech Jurczak, MD, PhD, Jagiellonian University, Krakow, Poland, talks on tafasitamab for the treatment of diffuse large B-cell lymphoma (DLBCL), highlighting a study which demonstrated the efficacy of patients treated with tafasitamab plus lenalidomide compared to patients treated with polatuzumab vedotin and CAR-T cell therapy. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter